. 2018 Dec 20;16:368. doi: 10.1186/s12967-018-1744-8

Table 4.

Association of the PCG-lncRNA signature with clinicopathological characteristics in postoperative GBM patients in TCGA dataset

Variables	Training set		P	Test set		P	Entire TCGA set		P
Variables	Low risk^a	High risk^a	P	Low risk^a	High risk^a	P	Low risk^a	High risk^a	P
Age			0.76			1			0.93
< 60	21	20		19	16		40	36
≥ 60	17	18		22	20		39	38
Sex			0.23			0.97			0.52
Female	10	16		16	13		26	29
Male	28	22		25	23		53	45
TMZ-chemotherapy			0.16			0.51			0.11
No	4	10		6	9		10	19
Yes	30	23		31	24		61	47
Unknown	4	5		4	3		8	8
Radiotherapy			0.01			0.26			0.01
No	1	7		5	8		6	15
Yes	36	26		36	27		72	53
Unknown	1	5		0	1		1	6
TMZ-chemoradiation			0.01			0.03			< 0.001
No	14	27		17	25		31	52
Yes	23	10		20	9		43	19
Unknown	1	1		2	4		3	5
Subtype			0.8			0.34			0.47
Classical	9	9		8	14		17	23
Mesenchymal	13	10		15	11		28	21
Neural	6	9		6	5		12	14
Proneural	10	10		11	6		21	16

^aLow risk ≤ median value of the PCG-lncRNA signature risk score, high risk > median of risk score in training group; The Chi-squared test; P value < 0.05 was considered significant; TMZ temozolomide